To investigate the risk and influencing factors of long-term liver adverse events in chronic hepatitis B patients achieving hepatitis B surface antigen(HBsAg)clearance after pegylated interferonα(Peg-IFNα)treatment,...To investigate the risk and influencing factors of long-term liver adverse events in chronic hepatitis B patients achieving hepatitis B surface antigen(HBsAg)clearance after pegylated interferonα(Peg-IFNα)treatment,a retrospective analysis was conducted on 456 patients at Beijing Ditan Hospital from 2008 to 2023 who achieved HBsAg clearance and discontinued Peg-IFNαtreatment.The baseline was defined as the time of HBsAg clearance and treatment cessation.The endpoint was the first occurrence of liver adverse events(hepatocellular carcinoma or ascites)or last follow-up.Subsequently,we evaluated the incidence and risk factors of liver adverse events,along with changes in liver fibrosis,cirrhosis,and liver function indicators.During a median follow-up of 70 months,the incidence of liver adverse events was 2.30%,hepatocellular carcinoma 1.76%,and ascites 0.55%.Older age and cirrhosis were significant risk factors(HR 1.075 and 41.393,both P<0.01).The APRI score significantly improved at follow-up compared to baseline(0.53 vs.0.25,P<0.001),and cirrhosis prevalence decreased from 5.70%to 0.88%(P<0.001).In conclusion,patients who achieved HBsAg clearance and discontinued Peg-IFNαtreatment have a low risk of liver adverse events,while advanced age and cirrhosis remain major risk factors.展开更多
基金funded by the Beijing Research Ward Ecxellence Program,BRWEP(BRWEP2024W102170101)the capital health research and development of special public health project(2022-1-2172)+3 种基金the National Key Research and Development Program(2022YFC2603500,2022YFC2603505,2023YFC2306901,2023YFC2308105,2023YFC2308105)the Beijing Municipal Health Commission high-level public health technical personnel construction project,discipline leader-03-26Beijing Hospitals Authority"peak"talent training program(DFL20241803)the Beijing Hospitals Authority Clinical medicine Development of special funding support(ZLRK202301).
文摘To investigate the risk and influencing factors of long-term liver adverse events in chronic hepatitis B patients achieving hepatitis B surface antigen(HBsAg)clearance after pegylated interferonα(Peg-IFNα)treatment,a retrospective analysis was conducted on 456 patients at Beijing Ditan Hospital from 2008 to 2023 who achieved HBsAg clearance and discontinued Peg-IFNαtreatment.The baseline was defined as the time of HBsAg clearance and treatment cessation.The endpoint was the first occurrence of liver adverse events(hepatocellular carcinoma or ascites)or last follow-up.Subsequently,we evaluated the incidence and risk factors of liver adverse events,along with changes in liver fibrosis,cirrhosis,and liver function indicators.During a median follow-up of 70 months,the incidence of liver adverse events was 2.30%,hepatocellular carcinoma 1.76%,and ascites 0.55%.Older age and cirrhosis were significant risk factors(HR 1.075 and 41.393,both P<0.01).The APRI score significantly improved at follow-up compared to baseline(0.53 vs.0.25,P<0.001),and cirrhosis prevalence decreased from 5.70%to 0.88%(P<0.001).In conclusion,patients who achieved HBsAg clearance and discontinued Peg-IFNαtreatment have a low risk of liver adverse events,while advanced age and cirrhosis remain major risk factors.
